Hepatic Drug Clearance: Restrictive and Nonrestrictive Clearance

Hepatic clearance is the volume of blood cleared of a drug by the liver per unit of time. It is calculated by subtracting renal clearance from total body clearance, though other elimination pathways like pulmonary or biliary routes may also contribute. This measurement is essential for understanding how quickly the liver eliminates drugs from the body.

Restrictive clearance is proportional to the unbound (free) fraction of a drug. When highly protein-bound drugs are displaced from their binding sites, their clearance substantially increases to levels comparable to low-protein-binding drugs. The hepatic drug clearance effect of protein binding demonstrates that only free drug is available for metabolism and elimination by the liver.

Restrictive clearance depends on the unbound drug fraction and protein binding, while nonrestrictive clearance applies to drugs extracted by the liver regardless of protein binding. Nonrestrictively cleared drugs are more easily separated from proteins during metabolism. This distinction affects how drug dosing and interactions must be managed clinically.

When intrinsic clearance is smaller than hepatic blood flow, hepatic clearance depends mainly on intrinsic clearance of both free and bound drug forms. However, when intrinsic clearance exceeds hepatic blood flow, hepatic clearance becomes primarily dependent on hepatic blood flow, independent of protein binding. This relationship determines the rate-limiting step in drug elimination.

The unbound fraction represents the active form of drug available for metabolism and elimination. Only free drug can be metabolized by hepatic enzymes, making protein binding a critical determinant of clearance for restrictively cleared drugs. Understanding unbound fraction helps predict how drug interactions and protein binding changes affect elimination rates.

When a highly protein-bound drug is displaced from its binding sites, the free drug concentration increases substantially, causing hepatic clearance to rise dramatically. The displaced drug becomes more available for hepatic metabolism, resulting in clearance levels approaching those of low-protein-binding drugs. This mechanism is clinically important for predicting drug interactions.

For drugs with high intrinsic clearance that exceeds hepatic blood flow, the liver cannot extract drug faster than blood delivers it. In these cases, hepatic clearance becomes flow-limited and depends primarily on hepatic blood flow rather than protein binding or intrinsic clearance. This explains why blood flow changes significantly impact elimination of high-extraction drugs.